The Relationship of Omega 3 Polyunsaturated Fatty Acids in Red Blood Cell Membranes with Cognitive Function and Brain Structure: A Review Focussed on Alzheimer’s Disease

Significant research attention has focussed on the identification of nutraceutical agents for the prevention of cognitive decline as a natural means of cognitive preservation in the elderly. There is some evidence for a reduction of brain omega 3 polyunsaturated fatty acids (n-3 PUFAs) in normal aging and in Alzheimer’s disease. n-3 PUFAs exhibit anti-inflammatory and anti-amyloidogenic properties as well as being able to reduce tau phosphorylation. Many observational studies have demonstrated a link between n-3 PUFAs and cognitive aging, and some, but not all, randomized controlled trials have demonstrated a benefit of n-3 PUFA supplementation on cognition, particularly in those subjects with mild cognitive impairment. The identification of a biomarker that reflects n-3 PUFA intake over time and consequent tissue levels is required. In this narrative review we discuss the evidence associating red blood cell membrane n-3 PUFAs with cognitive function and structural brain changes associated with Alzheimer’s disease.

[1]  S. Lehéricy,et al.  Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial , 2017, The Lancet Neurology.

[2]  K. Ladwig,et al.  Cognitive Impairment Is Associated with a Low Omega-3 Index in the Elderly: Results from the KORA-Age Study , 2016, Dementia and Geriatric Cognitive Disorders.

[3]  D. Bennett,et al.  APOE ε4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline , 2016, Neurology.

[4]  Anja Veronica Witte,et al.  Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment , 2016, NeuroImage.

[5]  Siddharth Gaikwad,et al.  The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: Acting separately or synergistically? , 2016, Progress in lipid research.

[6]  F. Ciruela,et al.  Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors , 2016, Scientific Reports.

[7]  A. Granholm,et al.  Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis , 2015, Molecular Neurobiology.

[8]  Simon C. Dyall,et al.  Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA , 2015, Front. Aging Neurosci..

[9]  Y. Surh,et al.  Docosahexaenoic acid induces M2 macrophage polarization through peroxisome proliferator-activated receptor γ activation. , 2015, Life sciences.

[10]  L. Tan,et al.  Association between stroke and Alzheimer's disease: systematic review and meta-analysis. , 2015, Journal of Alzheimer's disease : JAD.

[11]  P. Wong,et al.  Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid , 2014, Nature.

[12]  M. Weiner,et al.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA. , 2014, The journal of prevention of Alzheimer's disease.

[13]  J. Palmblad,et al.  Transfer of omega‐3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study , 2014, Journal of internal medicine.

[14]  T. Nettelbeck,et al.  Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n-3 fatty acids. , 2014, The Journal of nutrition.

[15]  Jennifer G. Robinson,et al.  Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes , 2014, Neurology.

[16]  J. Palmblad,et al.  ω-3 fatty acids in the prevention of cognitive decline in humans. , 2013, Advances in nutrition.

[17]  Jennifer G. Robinson,et al.  Omega-3 fatty acids and domain-specific cognitive aging , 2013, Neurology.

[18]  P. Mcgeer,et al.  The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy , 2013, Acta Neuropathologica.

[19]  J. Palmblad,et al.  Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. , 2013, Journal of Alzheimer's disease : JAD.

[20]  Steven R. Brenner,et al.  Penetrance of PD in Glucocerebrosidase Gene Mutation Carriers , 2012, Neurology.

[21]  Sarah A. Chau,et al.  Effects of omega-3 fatty acids on cognitive performance: a meta-analysis , 2012, Neurobiology of Aging.

[22]  A. Dangour,et al.  Omega 3 fatty acid for the prevention of cognitive decline and dementia , 2012, The Cochrane database of systematic reviews.

[23]  Thomas Meitinger,et al.  Genetic adaptation of fatty-acid metabolism: a human-specific haplotype increasing the biosynthesis of long-chain omega-3 and omega-6 fatty acids. , 2012, American journal of human genetics.

[24]  C. DeCarli,et al.  Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging , 2012, Neurology.

[25]  R. Stewart,et al.  Associations between n-3 PUFA concentrations and cognitive function after recovery from late-life depression. , 2012, The American journal of clinical nutrition.

[26]  D. Panagiotakos,et al.  Fish Consumption and Risk of Stroke , 2011, Women's health.

[27]  J. Buckley,et al.  Erythrocyte polyunsaturated fatty acid status, memory, cognition and mood in older adults with mild cognitive impairment and healthy controls. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  M. Péter,et al.  Docosahexaenoic Acid Reduces Amyloid β Production via Multiple Pleiotropic Mechanisms* , 2011, The Journal of Biological Chemistry.

[29]  Grace Y Sun,et al.  Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing , 2011, Neurochemistry International.

[30]  C. Serhan,et al.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. , 2010, Circulation research.

[31]  C. Holmes,et al.  Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy , 2010, Alzheimers Res Ther.

[32]  J. Lah,et al.  DHA diet reduces AD pathology in young APPswe/PS1ΔE9 transgenic mice: Possible gender effects , 2009, Journal of neuroscience research.

[33]  Tina L. Huang.  Omega-3 fatty acids, cognitive decline, and Alzheimer's disease: a critical review and evaluation of the literature. , 2010, Journal of Alzheimer's disease : JAD.

[34]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[35]  J. Lindsay,et al.  Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. , 2009, The American journal of clinical nutrition.

[36]  M. Vohl,et al.  Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE ɛ4 but not by the common PPAR-α L162V polymorphism in men , 2009, British Journal of Nutrition.

[37]  C. Tzourio,et al.  Vascular risk factors and dementia , 2009, Neurology.

[38]  Shih-Yi Huang,et al.  The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  P. Tso,et al.  The aging human orbitofrontal cortex: decreasing polyunsaturated fatty acid composition and associated increases in lipogenic gene expression and stearoyl-CoA desaturase activity. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[40]  Victoria J. Bourne,et al.  n–3 Fatty acid erythrocyte membrane content, APOE ε4, and cognitive variation: an observational follow-up study in late adulthood , 2008 .

[41]  J. Quinn,et al.  Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity. , 2008, Journal of Alzheimer's disease : JAD.

[42]  Victoria J. Bourne,et al.  n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. , 2008, The American journal of clinical nutrition.

[43]  P. Barberger-Gateau,et al.  Dietary patterns and risk of dementia , 2007, Neurology.

[44]  M. Lynch,et al.  Modulation of amyloid‐β‐induced and age‐associated changes in rat hippocampus by eicosapentaenoic acid , 2007, Journal of neurochemistry.

[45]  Takeo Kato,et al.  Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[46]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[47]  N. Bazan,et al.  Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection , 2007, Current opinion in clinical nutrition and metabolic care.

[48]  Yung-Hyun Choi,et al.  Inhibitory effects of eicosapentaenoic acid on lipopolysaccharide-induced activation in BV2 microglia. , 2007, International immunopharmacology.

[49]  G. Patton,et al.  Low serum docosahexaenoic acid is a significant risk factor for alzheimer’s dementia , 2007, Lipids.

[50]  J. C. Torre.  How do heart disease and stroke become risk factors for Alzheimer's disease? , 2006 .

[51]  W. Mojica,et al.  The Efficacy of Omega–3 Fatty Acids on Cognitive Function in Aging and Dementia: A Systematic Review , 2006, Dementia and Geriatric Cognitive Disorders.

[52]  K. Kristensson,et al.  Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease , 1991, Lipids.

[53]  L. H. Kuller,et al.  Benefits of fatty fish on dementia risk are stronger for those without APOE ε4 , 2005, Neurology.

[54]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[55]  M. Kodama,et al.  A case-control pilot study on n-3 polyunsaturated fatty acid as a negative risk factor for myocardial infarction. , 2005, International heart journal.

[56]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[57]  P. Zandi,et al.  Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. , 2005, Neurology.

[58]  Ian J Deary,et al.  Cognitive aging, childhood intelligence, and the use of food supplements: possible involvement of n-3 fatty acids. , 2004, The American journal of clinical nutrition.

[59]  C. Porter,et al.  Omega-3 Fatty Acids in Cardiac Biopsies From Heart Transplantation Patients: Correlation With Erythrocytes and Response to Supplementation , 2004, Circulation.

[60]  W. Markesbery,et al.  Regional Membrane Phospholipid Alterations in Alzheimer's Disease , 2004, Neurochemical Research.

[61]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[62]  B. Heude,et al.  Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study. , 2003, The American journal of clinical nutrition.

[63]  Lenore Arab,et al.  Biomarkers of fat and fatty acid intake. , 2003, The Journal of nutrition.

[64]  A. Simopoulos.  Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases , 2002, Journal of the American College of Nutrition.

[65]  T. Montine,et al.  Lipid peroxidation in aging brain and Alzheimer's disease. , 2002, Free radical biology & medicine.

[66]  M. Tierney,et al.  Fatty acid analysis of blood plasma of patients with alzheimer's disease, other types of dementia, and cognitive impairment , 2000, Lipids.

[67]  T. Lakka,et al.  Fish Oil–Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Coronary Events: The Kuopio Ischaemic Heart Disease Risk Factor Study , 2000, Circulation.

[68]  M. Lynch,et al.  Age-related changes in synaptic function: analysis of the effect of dietary supplementation with ω-3 fatty acids , 1999, Neuroscience.

[69]  B. Winblad,et al.  Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. , 1999, Archives of neurology.

[70]  P. Mcgeer,et al.  Inflammation of the brain in Alzheimer's disease: implications for therapy , 1999, Journal of leukocyte biology.

[71]  A. Muijtjens,et al.  Influence of age and sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects. , 1999, Clinical chemistry.

[72]  B. Halliwell,et al.  F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease , 1999, Journal of neurochemistry.

[73]  N. Noy,et al.  Ligand selectivity of the peroxisome proliferator-activated receptor alpha. , 1999, Biochemistry.

[74]  M. Lynch,et al.  Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. , 1999, Neuroscience.

[75]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[76]  S. Keli,et al.  Fish Consumption and Risk of Stroke: The Zutphen Study , 1994, Stroke.

[77]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[78]  D. Horrobin,et al.  Tin and fatty acids in dementia. , 1991, Prostaglandins, leukotrienes, and essential fatty acids.

[79]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.